Okyo Pharma Limited ADR (OKYO)

May 19, 2025, 7:00 AM EDT - 18 days ago

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

Apr 30, 2025, 7:00 AM EDT - 5 weeks ago

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

Mar 31, 2025, 8:00 AM EDT - 2 months ago

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

Jan 31, 2025, 7:00 AM EST - 4 months ago

OKYO Pharma Announces Chairman and CEO Acquire Shares

Jan 30, 2025, 9:45 AM EST - 4 months ago

Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited

Nov 15, 2024, 9:00 AM EST - 7 months ago

MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MUSQ

Oct 23, 2024, 7:00 AM EDT - 8 months ago

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

Aug 23, 2024, 9:00 AM EDT - 10 months ago

OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

SMXT

Aug 23, 2024, 9:00 AM EDT - 10 months ago

OKYO Pharma CEO Interview to Air on Bloomberg TV

Aug 23, 2024, 7:00 AM EDT - 10 months ago

OKYO Pharma Announces Chairman Acquires Shares

Aug 15, 2024, 12:13 PM EDT - 10 months ago

OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 6, 2024, 7:00 AM EDT - 10 months ago

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use

Jul 11, 2024, 7:00 AM EDT - 11 months ago

OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101

Jul 10, 2024, 7:00 AM EDT - 11 months ago

OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease

Apr 30, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

Apr 8, 2024, 7:00 PM EDT - 1 year ago

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

Apr 2, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

Mar 22, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Mar 21, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

Mar 20, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

Feb 9, 2024, 7:00 AM EST - 1 year ago

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

Jan 5, 2024, 9:30 AM EST - 1 year ago

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

Oct 9, 2023, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)

Sep 15, 2023, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares

Sep 14, 2023, 9:15 AM EDT - 1 year ago

OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares

Sep 14, 2023, 8:45 AM EDT - 1 year ago

OKYO Pharma Limited Announces Withdrawal of Public Offering

Sep 13, 2023, 4:05 PM EDT - 1 year ago

OKYO Pharma Announces Public Offering of Ordinary Shares

Sep 8, 2023, 7:00 AM EDT - 1 year ago

OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease

Aug 30, 2023, 7:00 AM EDT - 1 year ago

OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)

Aug 15, 2023, 9:00 AM EDT - 1 year ago

OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023

Jul 28, 2023, 5:25 PM EDT - 2 years ago

OKYO Pharma Announces Proposed Public Offering of Ordinary Shares

Jul 28, 2023, 5:05 PM EDT - 2 years ago

OKYO Pharma Limited Receives Nasdaq Deficiency Notice

Jul 28, 2023, 7:01 AM EDT - 2 years ago

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center

Jul 27, 2023, 11:30 AM EDT - 2 years ago

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer

Jun 6, 2023, 9:30 AM EDT - 2 years ago

OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease

May 3, 2023, 2:00 AM EDT - 2 years ago

OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023

May 2, 2023, 2:00 AM EDT - 2 years ago

OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease

Apr 25, 2023, 2:00 AM EDT - 2 years ago

OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease

Apr 18, 2023, 10:00 AM EDT - 2 years ago

OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay

Apr 5, 2023, 2:00 AM EDT - 2 years ago

Notice of General Meeting and Publication of Circular

Apr 4, 2023, 2:00 AM EDT - 2 years ago

Notice of Intention to Delist From The London Stock Exchange

Mar 30, 2023, 2:01 AM EDT - 2 years ago

OKYO Pharma Today Announces Director Acquires Shares

Mar 24, 2023, 3:00 AM EDT - 2 years ago

OKYO Pharma Announces PDMR Dealing

Mar 16, 2023, 3:01 AM EDT - 2 years ago

OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website

Mar 14, 2023, 3:00 AM EDT - 2 years ago

OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management

Mar 13, 2023, 4:15 PM EDT - 2 years ago

OKYO Pharma Limited Prices $5.3 Million Offering of ADSs

Feb 28, 2023, 2:00 AM EST - 2 years ago

OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease

Feb 23, 2023, 2:00 AM EST - 2 years ago

OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to Its Scientific Advisory Board

Dec 30, 2022, 2:00 AM EST - 2 years ago

OKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022

Dec 22, 2022, 2:00 AM EST - 2 years ago

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease